LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

12.1 -2.26

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.79

Max

12.38

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.4M -14M
Pelnas, tenkantis vienai akcijai	-0.15
Darbuotojai	37
EBITDA	-2.7M -15M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+154.63% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-241M 1.1B
Ankstesnė atidarymo kaina	14.36
Ankstesnė uždarymo kaina	12.1

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-01 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

2026-06-01 23:38; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

2026-06-01 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Dexus Stuck in 'Too Hard' Basket -- Market Talk

2026-06-01 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

2026-06-01 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Greg Abel's Week Is Off to Quite a Start -- WSJ

2026-06-01 21:53; UTC

Rinkos pokalbiai

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

2026-06-01 21:22; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-01 20:46; UTC

Įsigijimai, susijungimai, perėmimai

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

2026-06-01 20:22; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares $11 Special Div

2026-06-01 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

2026-06-01 19:40; UTC

Rinkos pokalbiai

Remittances to Mexico Rise for Third Straight Month -- Market Talk

2026-06-01 19:28; UTC

Rinkos pokalbiai

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

2026-06-01 19:01; UTC

Rinkos pokalbiai

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

2026-06-01 18:58; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

2026-06-01 18:54; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

2026-06-01 18:33; UTC

Rinkos pokalbiai

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

2026-06-01 18:32; UTC

Rinkos pokalbiai

Precious Metals Fall to Start June -- Market Talk

2026-06-01 18:00; UTC

Įsigijimai, susijungimai, perėmimai

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 17:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

154.63% į viršų

12 mėnesių prognozė

Vidutinis 31.6 USD 154.63%

Aukščiausias 40 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.